EVALUATION OF ANTI-BODY RESPONSE OF HEMODIALYSIS AND PERITONEAL DIALYSIS PATIENTS TO HEPATITIS-B VACCINE

Basit Öğe Kaydı
dc.contributor.authorAlcelik, Aytekin
dc.contributor.authorBicik, Zerrin
dc.contributor.authorBahcebasi, Talat
dc.contributor.authorAcikgoz, Elif
dc.contributor.authorYildirim, Mustafa
dc.contributor.authorOnder, Elif
dc.date.accessioned2024-09-25T19:58:37Z
dc.date.available2024-09-25T19:58:37Z
dc.date.issued2007
dc.departmentAbant İzzet Baysal Üniversitesien_US
dc.description.abstractObjective: Hemodialysis patients are at higher risk for Hepatitis B virus (HBV) infection when compared with the rest of the population. Adequate antibody response (approximately 90%) is achieved when healthy individuals are immunized with HBV vaccine; however, the response is about 50% and 70% in chronic renal failure (CRF) patients. In this study, it is aimed to assess the influence of different factors and the type of renal replacement, for antibody response to double dose of recombinant HBV-vaccine in dialysis patients. Materials and methods: In this retrospective study, we included 37 patients (19 males, 18 females) who were in the schedule of hemodialysis and continuous ambulatory peritoneal dialysis (CAPD) at the Dialysis Center of Duzce University Hospital between 2004 and 2005. The patients were administered double doses of recombinant DNA derived HBV vaccine IM for four times at 0, 1, 2, and 6 months. The patients' antibody responses were determined ated by ELISA test. Results: Six of the 37 patients (16.2%) had no response to the vaccine, while 15 patients (40.5%) had low response and 16 patients (43.2%) had complete response. There was no difference between hemodialysis patients and peritoneal dialysis patients in terms of the antibody response (p>0.05). Levels of hemoglobin, total cholesterol, triglyceride and albumin, type and duration of dialysis, and gender were not correlated with the antibody response (p>0.05). Conclusion: As a result, for dialysis patients, antibody response to the HBV-vaccine is lower than that in the healthy population and this decline in response seems to be multifactorial.en_US
dc.identifier.endpage43en_US
dc.identifier.issn1305-6433
dc.identifier.issn1305-6441
dc.identifier.issue2en_US
dc.identifier.startpage39en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12491/13667
dc.identifier.volume70en_US
dc.identifier.wosWOS:000409733700003en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isotren_US
dc.publisherIstanbul Univ, Faculty Medicine, Publishing Officeen_US
dc.relation.ispartofJournal of Istanbul Faculty of Medicine-Istanbul Tip Fakultesi Dergisien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmzYK_20240925en_US
dc.subjectHepatitis Ben_US
dc.subjectchronic renal insufficiencyen_US
dc.subjectvaccinationen_US
dc.titleEVALUATION OF ANTI-BODY RESPONSE OF HEMODIALYSIS AND PERITONEAL DIALYSIS PATIENTS TO HEPATITIS-B VACCINEen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu